Guiding Sufentanil Administration With Skin Conductance in Mechanically Ventilated Intensive Care Patients
Primary Purpose
Nociceptive Pain
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Skin conductance guided antinociception
Standard care antinociception
Sponsored by
About this trial
This is an interventional treatment trial for Nociceptive Pain
Eligibility Criteria
Inclusion Criteria:
- Adult patient admitted to the ICU requiring endotracheal intubation, antinociception, and sedation
Exclusion Criteria:
- Traumatic brain injury
- use of ketamine, dexmedetomidine, or clonidine
- pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Skin conductance guided
Standard care
Arm Description
Sufentanil is titrated by the intensive care team to maintain skin conductance in target
Sufentanil is titrated at the discretion of the intensivist
Outcomes
Primary Outcome Measures
Concentration of sufentanil requirements
Sufentanil requirements (µg/kg/h)
Secondary Outcome Measures
Concentration of propofol requirements
Propofol requirements (mg/kg/h)
Concentration of noradrenaline requirements (concentration of)
noradrenaline requirements (µg/kg/min)
Intubation time
Total time of mechanical ventilation (intubated)
Composite post extubation related complications
post extubation opioid related complications (e.g., delirium, vomiting, nausea, ileus, respiratory acidosis, hypoxemia, reintubation).
Full Information
NCT ID
NCT04696016
First Posted
January 4, 2021
Last Updated
February 1, 2021
Sponsor
Erasme University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04696016
Brief Title
Guiding Sufentanil Administration With Skin Conductance in Mechanically Ventilated Intensive Care Patients
Official Title
Guiding Sufentanil Administration With Skin Conductance in Mechanically Ventilated Intensive Care Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 1, 2021 (Anticipated)
Primary Completion Date
July 30, 2021 (Anticipated)
Study Completion Date
July 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Erasme University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Opioid administration in mechanically ventilated patients in the intensive care unit (ICU) is essential to maintaining patient respiratory and hemodynamic stability. Mechanical ventilation is a persistently nociceptive event that can continuously causes discomfort in the trachealy intubated patient. This can lead to patient-ventilator dyssynchrony, tachycardia, hypertension, and their associated complications. Opioids blunt respiratory drive, which facilitates mechanical ventilation, and decrease the sympathetic response to nociception. However, excessive opiate administration is associated with many adverse events, including respiratory depression, delirium, ileus, nausea, and vomiting. Currently, the standard administration in our institution of sufentanil, a potent opiate, consists of continuous infusions of 0.15µg/kg/h to 0.3µg/kg/h.
Mechanically ventilated patients are unable to speak and are often sedated. This greatly impacts the patient's capacity to communicate pain. The use of a nociceptive monitor may be a possible solution. Skin conductance monitoring (Pain Monitor, Med-Storm, Norway), measures the peaks per second of electrical conduction. This non hemodynamic monitor uses skin conduction as a surrogate to nociception (i.e., the patient's unconscious response to a noxious stimulus). It may consequently guide opioid administration in ICU patients towards and avoid the consequences of excessive or inadequate antinociception.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nociceptive Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Skin conductance guided
Arm Type
Experimental
Arm Description
Sufentanil is titrated by the intensive care team to maintain skin conductance in target
Arm Title
Standard care
Arm Type
Active Comparator
Arm Description
Sufentanil is titrated at the discretion of the intensivist
Intervention Type
Procedure
Intervention Name(s)
Skin conductance guided antinociception
Intervention Description
The value of skin conductance guides the titration of sufentanil
Intervention Type
Procedure
Intervention Name(s)
Standard care antinociception
Intervention Description
The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
Primary Outcome Measure Information:
Title
Concentration of sufentanil requirements
Description
Sufentanil requirements (µg/kg/h)
Time Frame
one day to 2 weeks
Secondary Outcome Measure Information:
Title
Concentration of propofol requirements
Description
Propofol requirements (mg/kg/h)
Time Frame
one day to 2 weeks
Title
Concentration of noradrenaline requirements (concentration of)
Description
noradrenaline requirements (µg/kg/min)
Time Frame
one day to 2 weeks
Title
Intubation time
Description
Total time of mechanical ventilation (intubated)
Time Frame
one day to 2 weeks
Title
Composite post extubation related complications
Description
post extubation opioid related complications (e.g., delirium, vomiting, nausea, ileus, respiratory acidosis, hypoxemia, reintubation).
Time Frame
one day to 2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patient admitted to the ICU requiring endotracheal intubation, antinociception, and sedation
Exclusion Criteria:
Traumatic brain injury
use of ketamine, dexmedetomidine, or clonidine
pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sean Coeckelenbergh
Phone
32 (0) 2 555 39 19
Email
sean.coeckelenbergh@ulb.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabio Taccone
Organizational Affiliation
Université Libre de Bruxelles
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Guiding Sufentanil Administration With Skin Conductance in Mechanically Ventilated Intensive Care Patients
We'll reach out to this number within 24 hrs